Athenex, Inc. (ATNXQ)

Market Cap	915.75K
Revenue (ttm)	102.82M
Net Income (ttm)	-103.43M
Shares Out	6.54M
EPS (ttm)	-15.81
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	113,028
Open	n/a
Previous Close	0.140
Day's Range	n/a
52-Week Range	0.081 - 0.230
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About ATNXQ

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through Oncology Innovation Platform and Commercial Platform segments. The company's Orascovery product candidates include Oral paclitaxel and encequidar for the treatment of metastatic breast cancer. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company engages in developing KUR-501, an auto...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jun 14, 2017
• Employees: 269
• Stock Exchange: OTCMKTS
• Ticker Symbol: ATNXQ

Financial Performance

In 2022, Athenex's revenue was $102.82 million, an increase of 7.81% compared to the previous year's $95.37 million. Losses were -$103.43 million, -48.23% less than in 2021.